Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
MADISON, Wis., April 22, 2025--(BUSINESS WIRE)--Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology.
B-Body Express™ allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express™ service to include standardized 2x1 and 2x2 B-Body® formats in the near future.
B-Body Express™ - Validation Scale Service Features:
Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales.
Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation.
Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility.
Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon.
Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms.
"Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "Our B-Body Express™ service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability."
The B-Body® platform is engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieve yields of 6–11 g/L, >95% purity after a single purification step, and exhibit excellent stability and viscosity profiles—ideal for subcutaneous administration and standard manufacturing workflows.
Starting from validated partner sequences, B-Body Express™ manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development.
About Invenra Inc.
Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the new B-Body Express™ service, to accelerate the journey of novel medicines to patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422436080/en/
Contacts
Bryan Glaser, Ph.D.Senior Vice President of Business Developmentbglaser@invenra.com 608-441-8319https://invenra.com/partnering/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
PrideStaff Named to Staffing Industry Analysts' List of Largest U.S. Staffing Firms for 13th Consecutive Year
FRESNO, Calif., June 13, 2025 /PRNewswire/ -- PrideStaff, a nationally franchised staffing organization, is pleased to announce it has been named to Staffing Industry Analysts' (SIA) 2025 List of Largest Staffing Firms in the United States. Ranked #113, PrideStaff has earned a spot on this influential list for the 13th consecutive year. The 2025 report includes 225 staffing companies, each of which generated at least $100 million in U.S. staffing revenue in 2024, a threshold fewer firms met than in previous years. According to SIA, these firms collectively represent 76.5% of the U.S. market by revenue, reflecting the ongoing consolidation and intense competition in the staffing industry. Despite economic fluctuations and a cooling labor market in many sectors, PrideStaff sustained its national growth trajectory, strengthened its franchise network, and deepened its focus on delivering exceptional service to clients and talent alike. PrideStaff's 2024 performance builds on its momentum as a leading United States staffing provider. With over 80 offices across North America, the organization continues to expand its footprint while innovating in technology, candidate experience, and workforce strategy. "It's incredibly rewarding to see our team's hard work recognized on SIA's list for the 13th straight year," said Tammi Heaton, PrideStaff Co-CEO. "This achievement reflects the adaptability of our model, the tenacity of our Owners/Strategic-Partners, and the full commitment of every team member across the nation to Our Mission: 'Consistently provide client experiences focused on what they value most.' This is especially important when workforce challenges are at their most complex." About PrideStaff PrideStaff was founded in the 1970s as 100% company-owned units and began franchising in 1995. It operates offices in North America to serve thousands of clients and is headquartered in Central California. With 45-plus years in the staffing business, PrideStaff offers the resources and expertise of a national firm, with the spirit, dedication, and personal service of smaller, entrepreneurial firms. PrideStaff is the only nationwide commercial staffing firm in the U.S. and Canada with over $100 million in annual revenue to earn ClearlyRated's prestigious Best of Staffing® 15-Year Diamond Awards two years in a row, highlighting exceptional client and talent service quality. For more information on our services, or staffing franchise information, visit our website. View original content to download multimedia: SOURCE Pridestaff, Inc
Yahoo
an hour ago
- Yahoo
CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study
Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab Veterinary Inc., a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, announced publication of a peer-reviewed pilot study demonstrating that ElenaVet™, the company's investigational p62-plasmid gene therapy, markedly reduced chronic osteoarthritis (OA) pain in companion dogs while exhibiting an excellent safety profile. The article, titled "Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study," appears in Frontiers in Veterinary Science (DOI 10.3389/fvets.2025.1519881). Key findings 17 client-owned dogs with radiographically confirmed OA received 1 mg intramuscular ElenaVet™ once a week for 10 weeks. Pain Severity Score (PSS) fell from 5.25 → 3.25 and Pain Interference Score (PIS) from 7.0 → 3.27 on the Canine Brief Pain Inventory (CBPI). 90% of dogs met the study's pre-defined "treatment success" criteria (≥1-point PSS drop and ≥2-point PIS drop). Quality-of-life ratings of "good/excellent" rose from 1 to 12 dogs. First owner-noticed improvements occurred within 2–4 weeks; scores plateaued by week 6. No significant adverse events—no vomiting, diarrhea, seizures, or lab abnormalities—were reported during treatment. Executive & scientific commentary"ElenaVet™ has now shown—in a rigorous, peer-reviewed setting—that a weekly gene-based therapy can deliver meaningful, durable pain relief without the organ-toxicity risks of long-term NSAID use," said Robert Devlin, general manager of CureLab Veterinary. "These results put us on a clear path toward larger, controlled trials and eventual U.S. approval." "The p62 plasmid dampens multiple inflammatory pathways simultaneously," added Vladimir Gabai, PhD, chief science officer and lead author of the study. "Because we encode p62 in a simple plasmid, we can administer a low-dose injection that teaches muscle cells to make the dog's own anti-inflammatory agent—no complex biologic manufacturing or cold chain required." Addressing a widespread unmet needOsteoarthritis affects an estimated one in five adult dogs; chronic use of standard NSAIDs can raise blood pressure, cause gastric ulcers and, in some cases, damage kidneys or liver. ElenaVet™ aims to offer a safer, compliance-friendly alternative—potentially as monthly or "as-needed" injections, once dose-frequency optimization studies are complete. Next stepsCureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols assessing dose range, durability of effect and long-term safety. With adequate funding, the company anticipates submitting a licensing application within 2–3 years. About ElenaVet™ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory mediators, providing multimodal relief from chronic inflammatory conditions such as osteoarthritis. About CureLab Veterinary Veterinary Inc. is a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company's mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners. The company's intellectual property portfolio, developed over the last decade, includes patents granted in more than 25 countries. To learn more, visit Investigational status / safe-harbor statementElenaVet™ is an investigational therapy not yet approved for commercial use; safety and efficacy have not been established by U.S. regulatory authorities. This press release contains forward-looking statements subject to risks and uncertainties. Media contactTim Cox | ZingPR for CureLab Veterinary | tim@ View original content to download multimedia: SOURCE CureLab Veterinary Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Invitation to Tecsys' Conference Call on June 27, 2025, Covering Fourth Quarter and Fiscal Year 2025 Results
MONTREAL, June 13, 2025 /CNW/ -- Tecsys Inc. (TSX: TCS) will release its financial results for the fourth quarter and fiscal year 2025 ended April 30, 2025, on June 26, 2025, after the markets close. Tecsys President and CEO Peter Brereton, and CFO Mark J. Bentler, will host a conference call on June 27, 2025, at 8:30 a.m. ET to present and discuss the results with the analysts. Subject: Q4 and FY2025 Financial Results Conference CallDate: June 27, 2025Time: 8:30 a.m. ETPhone number: 800-836-8184 or 646-357-8785 The call can be replayed until July 4, 2025, by calling 888-660-6345 or 646-517-4150 (access code: 07914 #). About Tecsys Tecsys is a global provider of advanced supply chain solutions. With a commitment to innovation and customer success, the company equips organizations with the essential software, technology and expertise needed for operational excellence and competitive advantage. Its cloud solutions serve a diverse range of industries, including healthcare, distribution and converging commerce, across multiple complex, regulated and high-volume markets. Built on the Itopia® low-code application platform, Tecsys' offerings include enterprise resource planning, warehouse management, consolidated service management, distribution and transportation management, supply management at the point of use and order management solutions. Tecsys provides critical data insights and control across the supply chain, ensuring that organizations are agile, responsive and scalable. Tecsys is publicly traded on the Toronto Stock Exchange under the ticker symbol TCS. For more about Tecsys and its solutions, please visit Forward Looking Statements The statements in this news release relating to matters that are not historical fact are forward looking statements that are based on management's beliefs and assumptions. Such statements are not guarantees of future performance and are subject to a number of uncertainties, including but not limited to future economic conditions, the markets that Tecsys Inc. serves, the actions of competitors, major new technological trends, and other factors beyond the control of Tecsys Inc., which could cause actual results to differ materially from such statements. More information about the risks and uncertainties associated with Tecsys Inc.'s business can be found in the MD&A section of the Company's annual report and the most recently filed annual information form. These documents have been filed with the Canadian securities commissions and are available on our website ( and on SEDAR+ ( Copyright © Tecsys Inc. 2025. All names, trademarks, products, and services mentioned are registered or unregistered trademarks of their respective owners. SOURCE Tecsys Inc. View original content to download multimedia: Sign in to access your portfolio
